Introduction:The term chemobrain is a short name for chemotherapy associated cognitive dysfunction.So far there is neither clear definition of the term chemobrain nor its epidemiology or pathogenesis are known and there have been no prospective studies addressing this condition.Method: Here, in this short review we provide an overview on the most recent findings of chemobrain pathogenesis, prevention and available treatment.We take a novel perspective on the role of blood-brain barrier in the development of chemotherapy associated cognitive dysfunction and discus briefly new and upcoming treatment. Results:The lack of knowledge, information and appropriate diagnostic and monitoring tools is particularly detrimental for elderly patients (>65 years) more susceptible to troublesome and life quality affecting cognitive dysfunctions.In the absence of effective preventive methods, raising awareness and educating patients about possible cognitive dysfunctions as a result of chemotherapy should be implemented. Conclusion:All cancer patients undergoing treatment and experiencing cognitive dysfunctions should be informed about the transient nature of the dysfunction and given options of either pharmacological or cognitive -behavioral therapy aimed at reducing the symptoms.
No takes yet. Share an insight, caveat, or question.
Banach et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: